Journal
TRENDS IN IMMUNOLOGY
Volume 37, Issue 3, Pages 193-207Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.it.2016.01.002
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA096651, R01 CA103320] Funding Source: Medline
- NIAID NIH HHS [R01 AI103347] Funding Source: Medline
Ask authors/readers for more resources
Indoleamine 2,3-dioxygenase (IDO) has immunoregulatory roles associated with tryptophan metabolism. These include counter-regulation (controlling inflammation) and acquired tolerance in T cells. Recent findings reveal that IDO can be triggered by innate responses during tumorigenesis, and also by attempted T cell activation, either spontaneous or due to immunotherapy. Here we review the current understanding of mechanisms by which IDO participates in the control of inflammation and in peripheral tolerance. Focusing on the tumor microenvironment, we examine the role of IDO in response to apoptotic cells and the impact of IDO on Treg cell function. We discuss how the counter regulatory and tolerogenic functions of IDO can be targeted for cancer immunotherapy and present an overview of the current clinical progress in this area.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available